AzTrials
AzTrials

Primary Hepatocellular CarcinomaEarly Phase 1NCT03672305

Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC

A Early Phase 1 study testing c-Met/PD-L1 CAR-T cell injection in people with Primary Hepatocellular Carcinoma, run by The Second Hospital of Nanjing Medical University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Title: Single-center, open clinical study on the efficacy and safety of c-Met/PD-L1 T cell injection in the treatment of primary hepatocellular carcinoma Stage: Phase I clinical trial Purpose: To evaluate the efficacy and safety of c-Met/PD-L1 CAR-T cells in patients with primary hepatocellular carcinoma Object… Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Primary Hepatocellular Carcinoma
What is being tested?
c-Met/PD-L1 CAR-T cell injection
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
No sites listed yet
Study dates
1 Oct 2018to 30 Oct 2019
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female patients aged 18 to 70 years (including 18 and 70 years);
  • Immune histochemistry detection was confirmed as c-met positive ; hepatocellular carcinoma, and the patient has no effective treatment at present
  • Liver tissue type: non-diffuse hepatocellular carcinoma, no extra hepatic metastasis or portal vein infiltration;
  • Cirrhosis of the liver: child-pugh A grade or child-pugh B grade, child-pugh-turcotte score <7;
  • Routine blood test: white blood cell count (WBC) or 3 * 10^9/L, lymphocyte percentage (LY) 15% or higher, hemoglobin (Hb), 90g/L or higher, prothrombin time (PT), international standardization ratio (INR) 1.7 or less, or prothrombin time (PT) extend the 4 s or less, lymphocyte acuity 0.8 * 10^9/L;
  • The main tissues and organs of the patients are functioning well (if the organs do not meet the following standards, but the researchers believe that the diseases themselves can be included):
Show all 16Show fewer
  • Hepatic and pancreatic functions: alanine aminotransferase/aspartate aminotransferase (ALT/AST) is 5 times of normal value, total bilirubin (TBiL) is 3.0mg/dL, albumin (ALB) is 35g/L, serum lipase is 1.5 times of normal value, and serum amylase is 1.5 times of normal value. Renal function: creatinine <2 ULN
  • Lung function: indoor oxygen saturation greater than or equal to 95% (without oxygen inhalation)
  • Cardiac function: LVEF is greater than or equal to 40%
  • The absolute number of neutrophils is greater than or equal to 0.75 * 10^9/L, and platelets are greater than or equal to 50 * 10^9/L
  • ECOG score 0-1 or Karnofsky performance status (card score) (KPS) is greater than 60, and the expected survival time is greater than or equal to 12 weeks;
  • There are adequate venipuncture or venous sampling channels and no contraindications for lymphocyte separation;
  • No anti-tumor therapy, including chemotherapy, radiotherapy and immunotherapy (such as immunosuppressive drugs), was received within 4 weeks before enrollment, and the toxicity response of previous treatment was restored to level 1 or less (except for low-level toxicity such as hair loss);
  • Female subjects of reproductive age must have negative serum or urine pregnancy test during screening, and male and female patients agree to take effective contraceptive measures during the trial;
  • There were no other serious complications;
  • Voluntarily sign informed consent.

Who cannot join

  • Women during pregnancy (positive urine/blood pregnancy test) or lactation; A male or female who has a plan to conceive within the last 1 year; Effective contraceptive (condom or birth control pill, etc.) cannot be guaranteed for 1 year after enrollment;
  • The patients had uncontrollable infection within 4 weeks before enrollment. However, prophylactic antibiotics, antiviral and antifungal infection treatment are allowed; Active hepatitis b hepatitis c; People infected with human immunodeficiency virus (HIV);
  • Suffering from severe autoimmune disease or immunodeficiency disease;
  • The patient is allergic to large molecular biological drugs such as antibodies or cytokines;
  • The patient who has mentally ill;
  • The patient has substance abuse/addiction;
Show all 21Show fewer
  • The patient who has a history of hepatocellular carcinoma;
  • Having severe peptic ulcer or bleeding;
  • A patient who receives an organ transplant or waits for one;
  • Patients requiring anticoagulation (e.g., warfarin or heparin);
  • Patients requiring long-term antiplatelet therapy (aspirin > 300 mg/d; Clopidogrel dose > 75 mg/d);
  • Organ failure patient:
  • Cardiac function: grade 3 or above according to the New York heart association (NYHA) standard
  • Liver function: C level above, according to child-pugh standard
  • Chronic kidney disease (CKD) stage 4 or above; Renal insufficiency or above
  • Lung function: severe respiratory failure, involving other organs
  • Brain function: abnormal central nervous system or disturbance of consciousness;
  • Systemic use of hormones within 4 weeks before enrollment (use of prednisone 20mg/ d or less is allowed, except for inhaled hormones);
  • The patient participated in other clinical trials within 4 weeks before enrollment;
  • The patient has been treated with radiation for the past four weeks;
  • Investigators determined that the patient was unable or unwilling to comply with protocol requirements.

Trial locations and contacts

No sites are listed yet.

Guozhong Ji, archiater contact

+86-13951031818

J58430@njmu.edu.cn

About this study

Official title: Single-center, Open Clinical Study on the Efficacy and Safety of c-Met/PD-L1 Chimeric Antigen Receptor T Cell Injection in the Treatment of Primary Hepatocellular Carcinoma

Title: Single-center, open clinical study on the efficacy and safety of c-Met/PD-L1 T cell injection in the treatment of primary hepatocellular carcinoma

Stage: Phase I clinical trial

Read more

Purpose: To evaluate the efficacy and safety of c-Met/PD-L1 CAR-T cells in patients with primary hepatocellular carcinoma

Object: patients with primary hepatocellular carcinoma

Sample size: 50 cases

Number of centres：1

Study design: CT, MRI, PET and blood biochemical tests were performed before treatment to evaluate the state of HCC. Peripheral blood of the patient was extracted and PBMC was isolated. CAR-T cells were obtained by tranducing PBMC with c-Met/PD-L1 CAR lentivirus, and the proliferation capacity and immune phenotype of the cells were tested. After passing the inspection, the cells were re-injected into the patient three times. The efficacy and safety of c-Met/PD-L1 CAR-T cells was assessed respectively at 4 week, 12 week, 24 week and 48 week after treatment.

Trial product: c-Met/PD-L1 CAR-T cells

Course of treatment: 3 days for a course of treatment, only one course of treatment. A second course is given as appropriate if the treatment is beneficial to the patient.

Read the detailed description

Title: Single-center, open clinical study on the efficacy and safety of c-Met/PD-L1 CAR-T cell injection in the treatment of primary hepatocellular carcinoma

Research purpose:

Primary outcome:

To evaluate the efficacy of c-Met/PD-L1 CAR-T cell injection in the treatment of primary hepatocellular carcinoma.

Secondary purpose:

  1. To evaluate the clinical safety of c-Met/PD-L1 CAR-T cell injection in the treatment of primary hepatocellular carcinoma;
  2. To assess the amplification and persistence of c-Met/PD-L1 CAR-T cells in subjects.

Study design:Single center, open clinical study

Subjects:Patients with primary hepatocellular carcinoma

Clinical trial cycle:

Screening stage:Selecting enrolled patients and collecting peripheral mononuclear cells; Treating stage: Pretreating and the backtransfusing c-Met/PD-L1 CAR-T cells Follow-up stage:Treatment was observed for 28 days (short-term follow-up), 28 days to 24 weeks (mid-term follow-up), and 24 weeks to progression/death (long-term follow-up);

Trial product:

Trial product:c-Met/PD-L1 CAR-T cells Dosage:The backtransfusion dose was determined by the investigator based on the subject's own/disease condition and in vitro preparation (recommended dose: 2 * 10^6/kg); Infusion way:Steady intravenous drip within 15 to 30 minutes

Clinical trial procedure:

  1. The screening period: The subjects signed the informed consent form and performed a series of examinations according to the interview flow chart. The researchers judged whether the subjects met the inclusion criteria according to the examination results and inclusion/exclusion criteria, and did not meet the exclusion criteria. If the subjects were enrolled, peripheral blood mononuclear cells were collected, and the collection standard was 2-4 * 10^8 white blood cells;
  2. nonmyeloablative pretreatment:(The following options are selected on a case-by-case basis)
  3. Fludarabine+Cyclophosphamide (FC)
  4. Bis-1-nitrosourea+Etoposide+Arabinoside+Cyclophosphamide (BECA);
  5. Retransfusion period: The specific time and dose of retransfusion can be determined by the researchers;
  6. Short-term follow-up period: Subjects will undergo a series of examinations according to the visit flow chart within 28 days after the expected dose of c-Met/PD-L1 CAR-T cells injection.The short-term efficacy and safety of c-Met/PD-L1 CAR-T cells injection were evaluated by the researchers based on the test results.
  7. Mid-term follow-up: Subjects will undergo a series of examinations according to the visit flow chart 28 days to 24 weeks after re-transfusion of c-Met/PD-L1 CAR-T cells injection.The researchers will evaluate the mid-term efficacy and safety of c-Met/PD-L1 CAR-T cells based on the test results.
  8. Long-term follow-up: Subjects will undergo a series of examinations according to the visit flow chart 24 weeks later until progress or death after retransfusion of c-Met/PD-L1 CAR-T cells.The long-term efficacy and safety of c-Met/PD-L1 CAR-T cells will be evaluated according to the test results.
  9. Withdrawal visit (at any time) :All subjects may withdraw from this study at any stage of the trial.If the subjects withdraw from the study after returning to the c-Met/PD-L1 CAR-T cells, they shall complete the inspection items required in the visit flow chart, and the reason for the withdrawal shall be recorded in detail by the researchers.If the subject passes screening but withdraws from the visit before returning to the c-Met/PD-L1 CAR-T cells, only the baseline and screening tests need to be completed, and the reason for withdrawal will be recorded in detail by the investigators.If the subject withdraws from the screening test before the end of the screening test, only the screening test shall be completed and the reason for withdrawal shall be recorded in detail by the investigators.If treatment is discontinued due to adverse reactions (AE), the investigators will follow up with the necessary safety until the subjects return to baseline or to a stable state.

Evaluation index Main evaluation index

  1. Objective tumor remission rate (ORR),complete remission (CR) and partial remission (PR) at 4 weeks, 12 weeks, 24 weeks and 48 weeks after treatment with c-Met/PD-L1 CAR-T cells;
  2. Overall survival
  3. Progression free survival
  4. Event-free survival

Secondary evaluation index

  1. Incidence of treatment-related adverse events (level 3 or level 4 adverse reactions, CTCAE V4.03 criteria). These included adverse events related to the treatment of c-Met/PD-L1 CAR-T cells, severe adverse events and clinically significant laboratory abnormalities;
  2. The amplification level of c-Met/PD-L1 CAR-T cells in the subjects varied with time;
  3. Duration of c-Met/PD-L1 CAR-T cells in the subjects;
  4. The abatement features of hepatocellular carcinoma in subjects.

Statistical analysis SPSS18.0 was used for statistical analysis

  1. The primary and secondary end points were analyzed by intentionality. The statistical analysis method of the end point was used to describe tumor ORR according to different follow-up time. Kaplan-meier method and survival curve were used to describe OS, PFS and EFS
  2. The statistical analysis method of the secondary study endpoint was to describe the occurrence number and incidence of treatment-related adverse events, and to compare the difference of vital signs and laboratory indexes before and after treatment
Being tested
c-Met/PD-L1 CAR-T cell injection
Medical subject headings
Carcinoma, Hepatocellular

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • c-Met/PD-L1 CAR-T cell injectionBiological

    injection content:c-Met/PD-L1 CAR-T cell Infusion way:Steady intravenous drip in 15 to 30 minutes

Study groups in NCT03672305
Study groupRoleWhat they receive
c-Met/PD-L1 CAR-T cells treating groupOtherIntervention Name:c-Met/PD-L1 CAR-T cell injection dosage form: injection dosage:The backtransfusion dose (recommended dose: 2 * 10^6/kg) was determined by the investigator based on the subject's own/disease condition and in vitro preparation.
Receives: Biological: c-Met/PD-L1 CAR-T cell injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The efficacy of c-Met/PD-L1 CAR-T cells in the treatment of HCC

    assessing the efficacy of c-Met/PD-L1 CAR-T cells through overall survival

    Measured: 6 months after treatment

Secondary outcomes (2)

  1. the incidence of treatment-emergent adverse events of c-Met/PD-L1 T cell injection in the treatment of HCC

    the level 3 or level 4 adverse reactions according to CTCAE V4.03 standard

    Measured: 6 months after treatment

  2. The amplification and persistence of c-Met/PD-L1 CAR-T cell in the subjects varied with time

    The amplification level of c-Met/PD-L1 CAR-T cells varied with time and the duration of anti-c-met/pd-l1 CAR-T cells in the subjects

    Measured: 6 months after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Sep 2018
  2. Study start1 Oct 2018 (estimated)
  3. Primary completion30 Oct 2019 (estimated)
  4. Study completion30 Oct 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03672305
Sponsor's protocol ID
JGZNO1
Status last verified
Sep 2018
First submitted
7 Sep 2018
Last updated
18 Sep 2018
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Li YW, Yang FC, Lu HQ, Zhang JS. Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol. 2016 Feb 14;22(6):1943-52. doi: 10.3748/wjg.v22.i6.1943.

    PubMed 26877602

  • McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015 May;19(2):223-38. doi: 10.1016/j.cld.2015.01.001. Epub 2015 Feb 26.

    PubMed 25921660

  • Tagliamonte M, Petrizzo A, Tornesello ML, Ciliberto G, Buonaguro FM, Buonaguro L. Combinatorial immunotherapy strategies for hepatocellular carcinoma. Curr Opin Immunol. 2016 Apr;39:103-13. doi: 10.1016/j.coi.2016.01.005. Epub 2016 Feb 4.

    PubMed 26851637

  • Kenderian SS, Ruella M, Gill S, Kalos M. Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res. 2014 Nov 15;74(22):6383-9. doi: 10.1158/0008-5472.CAN-14-1530. Epub 2014 Nov 4.

    PubMed 25371415

  • Pico de Coana Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med. 2015 Aug;21(8):482-91. doi: 10.1016/j.molmed.2015.05.005. Epub 2015 Jun 16.

    PubMed 26091825

  • Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17.

    PubMed 21849486

  • Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-71. doi: 10.1146/annurev-immunol-031210-101324.

    PubMed 21219185

  • Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther. 2009 Nov;20(11):1229-39. doi: 10.1089/hum.2009.142.

    PubMed 19702437

  • Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011 Nov;29(11):550-7. doi: 10.1016/j.tibtech.2011.04.009. Epub 2011 Jun 12.

    PubMed 21663987

  • Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.

    PubMed 22160384

  • Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

    PubMed 24553386

  • Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.

    PubMed 24876563

  • Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014 Apr 24;123(17):2625-35. doi: 10.1182/blood-2013-11-492231. Epub 2014 Feb 27.

    PubMed 24578504

  • Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014 Mar-Apr;20(2):119-22. doi: 10.1097/PPO.0000000000000035.

    PubMed 24667956

  • Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.

    PubMed 7165009

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing c-Met/PD-L1 CAR-T cell injection in people with Primary Hepatocellular Carcinoma, run by The Second Hospital of Nanjing Medical University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 16 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Guozhong Ji, archiater (+86-13951031818, J58430@njmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The efficacy of c-Met/PD-L1 CAR-T cells in the treatment of HCC (time frame: 6 months after treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03672305, which also lists 16 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2018.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in